Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
IBIO
IBIO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IBIO News
iBio Reports Q2 Financials with Increased Losses
6d ago
seekingalpha
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Dec 09 2025
NASDAQ.COM
iBio Reveals Promising Non-Human Primate Data for IBIO-610, an Activin E Antibody with Significant Potential for Targeted Weight Loss and Maintenance
Oct 30 2025
Newsfilter
iBio to Attend the 2nd Annual Healthcare Innovation Conference Hosted by Guggenheim
Oct 23 2025
Newsfilter
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Oct 23 2025
NASDAQ.COM
iBio to Showcase New Preclinical Findings on Its Activin E Antibody at ObesityWeek® and PEGS Europe 2025 Conferences
Oct 21 2025
Newsfilter
Leerink Partners Begins Coverage of iBio with Outperform Rating and Sets Price Target at $2
Oct 17 2025
Benzinga
Serina Therapeutics Stock Rises Over 25%; Check Out 20 Stocks Making Moves in Premarket Trading
Aug 26 2025
Benzinga
IBio Launches $50 Million Public Offering to Support Preclinical Antibody Initiatives
Aug 20 2025
NASDAQ.COM
Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target
Jun 25 2025
Benzinga
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
Jun 24 2025
Newsfilter
Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Jun 24 2025
Benzinga
US Stocks Likely To Open Higher After Trump Announces Iran-Israel Ceasefire: FedEx, TD Synnex In Focus Ahead Of Earnings
Jun 24 2025
Benzinga
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
Jun 16 2025
Newsfilter
iBio Raises $6.2 Million Through Warrant Inducement Transaction
Apr 29 2025
Newsfilter
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
Apr 22 2025
Newsfilter
Show More News
